baha the information company

Baha es un proveedor líder de datos de mercado en tiempo real, noticias financieras, tecnología y soluciones para la industria financiera. Baha ofrece terminales de datos en tiempo real para profesionales, datos de mercados financieros globales que cubren más de 12 millones de instrumentos financieros en más de 150 bolsas, así como noticias de última, hora 24 horas al día, 7 días a la semana, con cobertura global y aplicaciones web y móviles gratuitas. De un total de unos 200 proveedores de datos en tiempo real en todo el mundo, solo Reuters 1851, Bloomberg 1981 y ahora Baha en 2021 llevan el nombre del fundador.

DZ Bank Knock-Out REGN/ DE000DJ5V3A3 /

11/11/2024 21:37:48	Diferencia-0.040	Bid22:00:31	Ask22:00:31	Subyacente	Precio de ejercicio	Fecha de expiración	Tipo de opción
0.830EUR	-4.60%	- Volumen de oferta: -	- Tamaño/ Volumen/ Formato de Ask: -	Regeneron Pharmaceut...	737.1549 USD	31/12/2078	Call

GlobeNewswire 28/08 Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

GlobeNewswire 26/08 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...

GlobeNewswire 26/08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 21/08 Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewswire 15/08 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...

GlobeNewswire 15/08 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...

GlobeNewswire 12/08 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...

GlobeNewswire 08/08 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...

GlobeNewswire 07/08 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

GlobeNewswire 05/08 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 01/08 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 31/07 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

GlobeNewswire 23/07 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 23/07 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

GlobeNewswire 16/07 Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

GlobeNewswire 10/07 Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire 07/07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 03/07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 03/07 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

GlobeNewswire 30/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 28/06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 27/06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 22/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

DZ Bank Knock-Out REGN/ DE000DJ5V3A3 /

Si desea recibir la respuesta a sus comentarios, por favor proporcione su dirección de correo electrónico.